Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?

Objective: To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or enzalutamide) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), including sequential therapy and combined therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ming-kun, Liang, Zhi-jian, Luo, Dao-Sheng, Xue, Kang-yi, Liao, De-ying, Li, Zheshen, Yu, Yuzhong, Chen, Zhe-Sheng, Zhao, Shan-Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891580/
https://www.ncbi.nlm.nih.gov/pubmed/35250590
http://dx.doi.org/10.3389/fphar.2022.843110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891580/
https://www.ncbi.nlm.nih.gov/pubmed/35250590
http://dx.doi.org/10.3389/fphar.2022.843110

Ejemplares similares